



CONSIDE

CONSORTIUM FOR THE STANDARDIZATION
OF INFLUENZA SEROEPIDEMIOLOGY

Planning a new MN/HI collaborative study


John Wood

CONSIDE 4th International Meeting, Cape Town South Africa

3-4 September 2013

Background

- Have consensus protocols for 2 day and 3 day MN assays
 - CONSIZE MN collaborative study compared 2 and 3 day protocols for H1N1pdm09 assays using locally-derived sera
 - Could compare 2 day and 3 day assay within a lab but couldn't examine variability between labs as sera not shared
 - Don't know whether having consensus MN assays will improve between-lab agreement
 - Don't know whether an antibody standard will improve between-lab agreement
- Have consensus protocol for HI assay (close to WHO manual)
 - Need to examine whether a consensus HI assay protocol will improve between-lab agreement
- Agreed at Hong Kong CONSIZE meeting
 - To compare consensus MN and HI assay protocols versus local protocols
 - To test the same panel of sera in all labs
 - For NMRC to check availability of serum samples
 - To use locally grown stocks of reference virus



Plan for MN/HI collaborative study

Reference virus strain

- Propose to use H1N1pdm09 as sera available for this strain and we have data confirming 2 day and 3 day MN assays may be used interchangeably

Serum panel

- NMRC (Nick Martin) to describe serum panels available.
- Ideally need approx. 10 sera of low, medium and high titre, approx. 10 ml each.

Lab materials

- All labs to supply own reagents

Assays

- Labs should assay all sera by either 2 day or 3 day consensus MN assay protocol and local MN assay protocol and/or by consensus HI assay protocol and local HI assay protocol
- Three assay comparisons should be made

Antibody Standards

- The WHO International Standard for H1N1pdm09 antibody, Mab and antibody sourced from animals should be evaluated

